Skip to main content

Table 2 Rituximab maintenance versus retreatment: comparison of efficacy

From: B cell non-Hodgkin's lymphoma: rituximab safety experience

  Maintenance Retreatment P
Overall response rate (%) 52% 35% 0.14
Complete response rate (%) 27% 4% 0.007
% in continuous remission 45% 24% 0.05
% remaining in continuous remission 23% 2% 0.03
Median progression-free survival (months) 31.7 7.4 0.007
Median duration of rituximab benefit (months) 31.7 27.4 0.94